Oral VK2735 Phase 2 data at ECO 2026: up to 12.2% weight loss at 13 weeks
Viking presented data on VK2735 (oral tablet) for Obesity at a medical meeting on May 12, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Viking Therapeutics, Inc. VKTX
- Drug
- VK2735 (oral tablet)
- For
- Obesity
- Stage
- Phase 2 · the stage that tests whether the drug actually works
- When
- May 12, 2026
- Source note
- Viking presented the 13-week VENTURE-Oral Dosing dataset at the European Congress on Obesity, showing dose-dependent mean weight loss up to 12.2% with no plateau. Baseline characteristics from the ongoing Phase 3 VANQUISH-1 study were shown in a second poster.
- Checked
- Checked by a person when it was added
- Source: prnewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- VKTX headlines on this site
Initiation of Phase 3 program for oral VK2735, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Viking (VK2735 (oral) for Obesity): a step in the program rather than a decision or a data readout.
More details
- Entry
- Initiation of Phase 3 program for oral VK2735 · Company milestone
- Drug
- VK2735 (oral)
- For
- Obesity
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- Q2 2026 PR: oral VK2735 Phase 3 'expected to begin in the fourth quarter of this year' following positive 13-week Phase 2 VENTURE-Oral data.
- Checked
- Checked by a person when it was added
- Verify it
- Source: prnewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- VKTX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Viking expects to report results from its Phase 3 study of VK2735 (subcutaneous) for Obesity (VANQUISH-1, n~4,650) and obesity/overweight with T2D (VANQUISH-2, n~1,000) during 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- VANQUISH-1 and VANQUISH-2 Phase 3 topline (subcutaneous VK2735 in obesity/T2D) · Clinical trial results (readout / topline data)
- Drug
- VK2735 (subcutaneous)
- For
- Obesity (VANQUISH-1, n~4,650) and obesity/overweight with T2D (VANQUISH-2, n~1,000)
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- 2027 · the company gave a window, not a day
- Source note
- Both 78-week trials are fully enrolled (VANQUISH-1 Nov 2025, VANQUISH-2 Mar 2026) and 'proceeding according to plan'; coverage of company guidance points to completion/data in 2027 (some coverage says late 2027). Company has not press-released a specific topline quarter, hence year precision and MEDIUM.
- Checked
- Checked by a person when it was added
- Verify it
- Source: finance.yahoo.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- VKTX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page